Nephroblastoma treatment market

Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI5192
156 Pages
Excel & Pdf
Pharmaceutical

Summary

The rare kidney cancer nephroblastoma, sometimes called wilms' tumor, typically affects young people. Children with nephroblastoma are most frequently affected between the ages of 3 and 4, cases after age 5 are substantially less prevalent. Although it can occasionally be seen in both kidneys at the same time, nephroblastoma typically only affects one kidney. When cells experience DNA errors, cancer develops. The errors cause the cells to grow and divide uncontrollably. The accumulating cells then form a tumor. This process takes place in the kidney cells in nephroblastoma.

Global nephroblastoma treatment market is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030).

Figure 1.Global Nephroblastoma Treatment Market Share (%), by Type, 2022

Increasing approvals from regulatory bodies to key players for nephroblastoma treatment in market are expected to drive growth of the nephroblastoma treatment market.

Key players in market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, in May 2022, Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial, which would have a starting dose of 1 mg/kg for the treatment of wilms’ tumor 1 (WT1)-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers.

Nephroblastoma Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,653.0 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	4.6%	2030 Value Projection:	US$ 2,366.5 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Favorable histology, Anaplastic histology By Drug Type: Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
Growth Drivers:	Increasing approvals from regulatory bodies to key players for the nephroblastoma treatment Rising research and development activities by key players for the treatment of nephroblastoma
Restraints & Challenges:	High treatment cost of nephroblastoma

Figure 2.Global Nephroblastoma Treatment Market Share (%), by Distribution Channel, 2022

Rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth during the forecast period.

Key players in market are focused on carrying out research and development activities for the development of drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, the Children's Oncology Group, a clinical trials group supported by the National Cancer Institute, is currently studying the effect of combination chemotherapy and surgery in treating young patients with wilms tumor. As of August 4, 2022, the study is currently in phase 3 of its clinical trial and the study is expected to be completed by November 2023.

Global Nephroblastoma Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another.

The COVID-19 pandemic had a negative economic impact on the global nephroblastoma treatment market, owing to the delay in routine screening of cancer. For instance, according to an article published by the National Center for Biotechnology Information, in September 2021, on March 16, 2020, the U.K., postponed routine screening for cancer in response to the COVID-19 pandemic.

Global Nephroblastoma Treatment Market: Restraint

The major factor that hinders growth of the global nephroblastoma treatment market includes high treatment cost of nephroblastoma. For instance, according to an article published by the American Society of Clinical Oncology, in November 2018, the cost for a full course of treatment and follow-up was determined to be between US$ 1,490 and US$ 2,093 for a patient with nephroblastoma according to the study at the Butaro Cancer Center of Excellence (BCCOE), located at the Butaro District Hospital in rural northern Rwanda, Central Africa.

Key Players

Major players operating in the global nephroblastoma treatment market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals.

Table of Content

Table of Contents

*Browse 41 market data tables and 43 figures on "Nephroblastoma Treatment Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global nephroblastoma treatment market during the forecast period (2022-2030)?

The global nephroblastoma treatment market size is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing approvals from regulatory bodies to key players for the nephroblastoma treatment and rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth.

Which is the leading type segment in the market?

Favorable histology is the leading type segment in the market.

What are the key factors hampering growth of the market?

The major factor hampering growth of the market includes high treatment cost of nephroblastoma.

Which are the major players operating in the market?

Major players operating in the market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals.